- Biopharma M&A maintains strength even as large deals waneBiopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: meg…Endpoints · 2mo ago↗ source
- Amgen expands crackdown on what it says is misuse of 340B programAmgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud…Endpoints · 2mo ago↗ source
- Candel reports prostate cancer drug's long-term data ahead of FDA filingCandel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…